Scholl S - Search Results

1

Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients.

Winkelmann N, Desole M, Hilgendorf I, Ernst T, Sayer HG, Kunert C, Mügge LO, Hochhaus A, Scholl S. Winkelmann N, et al. Among authors: scholl s. J Cancer Res Clin Oncol. 2016 Dec;142(12):2603-2610. doi: 10.1007/s00432-016-2270-9. Epub 2016 Sep 17. J Cancer Res Clin Oncol. 2016. PMID: 27640002

2

Allogeneic blood stem cell transplantation in advanced chronic myeloid leukemia--high response rate associated with increased chronic graft-versus-host disease.

Sayer HG, Kasper C, Mügge LO, Schilling K, Scholl S, Höffken K. Sayer HG, et al. Among authors: scholl s. Haematologica. 2003 Jul;88(7):831-3. Haematologica. 2003. PMID: 12857566 No abstract available.

3

Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors.

Kasper C, Sayer HG, Mügge LO, Schilling K, Scholl S, Issa MC, Höffken K. Kasper C, et al. Among authors: scholl s. Bone Marrow Transplant. 2004 Jan;33(1):65-9. doi: 10.1038/sj.bmt.1704299. Bone Marrow Transplant. 2004. PMID: 14704658 Clinical Trial.

4

Signal transduction of c-Kit receptor tyrosine kinase in CHRF myeloid leukemia cells.

Scholl S, Kirsch C, Böhmer FD, Klinger R. Scholl S, et al. J Cancer Res Clin Oncol. 2004 Dec;130(12):711-8. doi: 10.1007/s00432-004-0602-7. Epub 2004 Aug 31. J Cancer Res Clin Oncol. 2004. PMID: 15340843

5

Increase of interleukin-18 serum levels after engraftment correlates with acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation.

Scholl S, Sayer HG, Mügge LO, Kasper C, Pietraszczyk M, Kliche KO, Clement JH, Höffken K. Scholl S, et al. J Cancer Res Clin Oncol. 2004 Dec;130(12):704-10. doi: 10.1007/s00432-004-0603-6. Epub 2004 Sep 7. J Cancer Res Clin Oncol. 2004. PMID: 15365821

6

Impact of early NK cell recovery on development of GvHD and CMV reactivation in dose-reduced regimen prior to allogeneic PBSCT.

Scholl S, Mügge LO, Issa MC, Kasper C, Pachmann K, Höffken K, Sayer HG. Scholl S, et al. Bone Marrow Transplant. 2005 Jan;35(2):183-90. doi: 10.1038/sj.bmt.1704752. Bone Marrow Transplant. 2005. PMID: 15531897

7

Analyses of minimal residual disease based on Flt3 mutations in allogeneic peripheral blood stem cell transplantation.

Scholl S, Loncarevic IF, Krause C, Clement JH, Höffken K, Sayer HG. Scholl S, et al. J Cancer Res Clin Oncol. 2005 May;131(5):279-83. doi: 10.1007/s00432-004-0660-x. Epub 2005 Jan 11. J Cancer Res Clin Oncol. 2005. PMID: 15645287

8

Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia.

Scholl S, Loncarevic IF, Krause C, Kunert C, Clement JH, Höffken K. Scholl S, et al. Leuk Res. 2005 Jul;29(7):849-53. doi: 10.1016/j.leukres.2004.12.001. Leuk Res. 2005. PMID: 15921740

9

Specific detection of Flt3 point mutations by highly sensitive real-time polymerase chain reaction in acute myeloid leukemia.

Scholl S, Krause C, Loncarevic IF, Müller R, Kunert C, Wedding U, Sayer HG, Clement JH, Höffken K. Scholl S, et al. J Lab Clin Med. 2005 Jun;145(6):295-304. doi: 10.1016/j.lab.2005.03.005. J Lab Clin Med. 2005. PMID: 15976757

10

Safety and impact of donor-type red blood cell transfusion before allogeneic peripheral blood progenitor cell transplantation with major ABO mismatch.

Scholl S, Klink A, Mügge LO, Schilling K, Höffken K, Sayer HG. Scholl S, et al. Transfusion. 2005 Oct;45(10):1676-83. doi: 10.1111/j.1537-2995.2005.00578.x. Transfusion. 2005. PMID: 16181220 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

324 results

Search Page

Filters